FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review

Friday, August 7, 2020 1 min read

Key Takeaway: FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review

Full Press Release Details

FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review.